Sirtex Announces New Medical Director for U.S. Operations.LAKE FOREST, Ill. -- Sirtex, a leading developer of targeted and innovative cancer therapies, is pleased to name Dr. David Cade as its first medical director for U.S. Operations. Dr. Cade previously served as European Medical Director for Sirtex in Bonn, Germany. Sirtex manufactures SIR-Spheres(R) microspheres, the only FDA-approved radioactive microspheres for treatment of metastatic MetastaticThe term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. liver tumors. The company's U.S. headquarters are in Lake Forest, Ill. Dr. Cade joined Sirtex in 2003 after serving as a global associate at Booz Allen Hamilton Booz Allen Hamilton, Inc., referred to as Booz Allen is one of the oldest strategy consulting firms in the world.[1] The firm formerly had two consulting divisions: WCB (Worldwide Commercial Business, also known as “The Commercial Side”) and WTB in Melbourne, Australia. Previously, he held a cardiothoracic surgery teaching position at the Monash Medical Centre Monash Medical Centres (MMC) is a multicampus teaching hospital in Melbourne, Victoria, Australia. The Clayton campus is in Clayton, the Moorabbin Campus at East Bentleigh. It provides specialist care to the State's south-east. in Melbourne, Australia. Dr. Cade received his Bachelor of Medicine Noun 1. Bachelor of Medicine - (a British degree) a bachelor's degree in medicine MB bachelor's degree, baccalaureate - an academic degree conferred on someone who has successfully completed undergraduate studies Britain, Great Britain, U.K. Bachelor of Surgery degree from Monash University and a Masters degree in Business Administration from the Melbourne Business School Melbourne Business School (MBS) is the largest business school in Asia Pacific and a leader in management education and executive development. Over the last 50 years, we have built an outstanding reputation for program excellence and a high quality learning experience. in Melbourne, Australia. "We are very excited to have Dr. Cade join our U.S. operations," says Charles Rowland, president of Sirtex Medical. "Our mission in 2006 is to advance our training and education programs to better serve physicians who administer SIR-Spheres microspheres. Dr. Cade will also play an integral role in the development of our clinical research strategy." Sirtex's SIR-Spheres microspheres are radioactive polymer spheres that emit beta radiation. Physicians insert a catheter through the groin into the hepatic artery and deliver millions of SIR-Spheres microspheres directly to the tumor site. The SIR-Spheres microspheres target the liver tumors, sparing healthy liver tissue. Clinical research shows that the use of SIR-Spheres microspheres increases patient survival rates by an average of five to six months. Approximately 55 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 60 medical centers. The minimally invasive procedure Minimally invasive surgical procedures avoid open invasive surgery in favor of closed or local surgery with less trauma. These procedures involve use of laparoscopic devices and remote-control manipulation of instruments with indirect observation of the surgical field through an is performed on an out-patient basis with minor side effects. About Sirtex SIR-Spheres microspheres were developed in the 1980s in Australia and gained FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval in March 2002. Sirtex has obtained regulatory approval to market SIR-Spheres microspheres in the United States, European Union, Israel and Australia. The product is marketed in New Zealand, Hong Kong, Malaysia, Singapore and Thailand. For more information, visit www.sirtex.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion